Treatment News : HIV-Positive People on Abacavir Don’t Have More Inflammation

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » July 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


July 1, 2010

HIV-Positive People on Abacavir Don’t Have More Inflammation

HIV-positive women and men do not appear to have increased signs of cardiovascular inflammation when they take abacavir (found in Ziagen, Epzicom and Trizivir), according to a study published online June 25 in the journal AIDS. These results stand in contrast to a couple of previous studies that found not only higher levels of inflammatory proteins in abacavir takers, but also an increased risk for heart attacks.

Members of the HIV community were surprised when the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study reported in February 2008 that people using abacavir had about a 90 percent increase in the likelihood of having a heart attack. A subsequent analysis of data from the Strategies for Management of Anti-Retroviral Therapy (SMART) study confirmed these findings.

The SMART and D:A:D studies also found that abacavir was associated not only with an increased heart attack risk, but also with an increase in blood levels of proteins that are often associated with cellular inflammation in the circulatory system, and an increased risk of cardiovascular disease (CVD). Contrary to D:A:D and SMART, however, several subsequent studies from large cohorts found no consistent increase in either heart attack risk or inflammatory protein levels in abacavir takers.

To explore this matter, Frank Palella, MD, from Northwestern University Feinberg School of Medicine in Chicago, and his colleagues analyzed data from two large U.S. studies: the Women’s HIV Interagency Cohort Study (WHIS) and the Multicenter AIDS Cohort study (MACS). In all, Palella’s team looked at blood levels of inflammatory proteins in 1,508 women and men before and after they started taking potent combination ARV therapy. Though none of these people were on combination therapy at the first study visit included in the analysis, some were taking one or two ARV drugs before beginning combination therapy.

Half the group started a regimen that included abacavir, and half did not include abacavir in their regimen. The two groups were matched based on a number of factors so as to ensure that they were as similar as possible. The study looked for changes in three inflammatory proteins—interleukin-6 (IL-6), high sensitivity C-reactive protein (hsCRP) and D-dimer—but not heart attacks.

Palella and his colleagues found abacavir was not associated with differences in inflammatory protein levels. This was true whether people were initiating ARV therapy for the first time, or had taken it at some point in the past.

The authors caution that, “This work should not be interpreted as either refuting or supporting hypotheses suggesting associations between recent use of abacavir (or any other [ARV drug] for that matter) and CVD in general or specific CVD endpoints.

“However, our work does suggest that, if recent [abacavir] use is indeed associated with increase risk for adverse cardiovascular events, system inflammation is not likely the sole or primary means by which its effects are mediated,” they conclude.

Search: abacavir, Ziagen, Epzicom, Trizivir, cardiovascular, inflammation, heart attack, D:A:D, SMART, WHIS, MACS, Frank Palella

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.